TrialThe Journal of urology2013

Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.

Mostafa M Elhilali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.